KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Long-Term Deferred Tax: 2012-2013

  • Sarepta Therapeutics' Long-Term Deferred Tax rose 17.09% to $133.6 million in Q4 2013 from the same period last year, while for Dec 2013 it was $133.6 million, marking a year-over-year increase of 17.09%. This contributed to the annual value of $133.6 million for FY2013, which is 17.09% up from last year.
  • Latest data reveals that Sarepta Therapeutics reported Long-Term Deferred Tax of $133.6 million as of Q4 2013, which was up 17.09% from $114.1 million recorded in Q4 2012.
  • In the past 5 years, Sarepta Therapeutics' Long-Term Deferred Tax registered a high of $133.6 million during Q4 2013, and its lowest value of $114.1 million during Q4 2012.
  • For the 2-year period, Sarepta Therapeutics' Long-Term Deferred Tax averaged around $123.8 million, with its median value being $123.8 million (2012).
  • Data for Sarepta Therapeutics' Long-Term Deferred Tax shows a peak YoY climbed of 17.09% (in 2013) over the last 5 years.
  • Quarterly analysis of 2 years shows Sarepta Therapeutics' Long-Term Deferred Tax stood at $114.1 million in 2012, then increased by 17.09% to $133.6 million in 2013.